ClinicalTrialsFinder
RecruitingNCT05336851

Emergency PWAS in Respiratory Infectious Disease

Emergency PanorOmic Wide Association Study in Respiratory Infectious Disease (ePWAS-RID)

Sponsor

The University of Hong Kong

Enrollment

2,000 participants

Start Date

Apr 11, 2023

Study Type

OBSERVATIONAL

Summary

Develop an emergency PanorOmics Wide Association Study (ePWAS) for the early, rapid biological and pathophysiological characterisation of known and novel Infectious Diseases in adult patients presenting to emergency departments with suspected, acute, community-acquired respiratory infectious disease (scaRID). Phase 1 1. Develop an ED-ID biobank (named ePWAS-RID). Phase 2 2. Targeted research for the discovery of novel diagnostics, prognostics and therapeutics

Eligibility

Min Age: 18 YearsMax Age: 100 Years

Inclusion Criteria18

  • Patients eligible for enrolment include:
  • Adults ≥18 years of age; AND
  • Suspected, acute, community-acquired, respiratory, infectious disease (scaRID)*; AND
  • Informed consent.
  • Note: scaRID is defined according to ALL three criteria:
  • Community acquired (not hospitalised for <28 days); AND
  • Acute infection (defined as symptom onset <8 days and any ONE of reported fever or chills or aural temperature >37.5°C or hypothermia or leucocytosis or leucopaenia or new altered mental status); AND
  • Probable respiratory infection - According to any ONE of:
  • new cough or new sputum production or
  • chest pain or
  • dyspnoea or
  • tachypnoea or
  • abnormal lung examination or
  • respiratory failure; or
  • physician's judgment (presenting with systemic or gastrointestinal symptoms).
  • Control subjects will be drawn from two groups:
  • The worried well - adult patients with a National Early Warning Score (NEWS) <3 and a temperature <37.5°C.
  • Relatives or accompanying friends with no acute illness.

Exclusion Criteria16

  • Refusal of consent;
  • Recent hospitalisation (<28 days);
  • Enrolled in another clinical trial
  • Cellulitis;
  • Skin or orthopaedic infections;
  • Urinary tract infection;
  • Acute abdominal sepsis;
  • Sexual transmitted disease;
  • Human immunodeficiency virus (HIV) infection;
  • Immunocompromised/potential neutropenic fever;
  • Solid organ or haematopoietic stem-cell transplant within the previous 90 days;
  • Active graft-versus-host disease or bronchiolitis obliterans;
  • Severe traveller's disease requiring urgent hospitalisation and management including malaria, dengue, typhoid and other rickettsial diseases;
  • Stroke;
  • Toxidrome;
  • Non-organic acute psychosis.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTBiomarker blood draw and saliva collection

Three peripheral 10 - 20mL blood sample (if available) Three 1 - 5mL salivary samples (if available)

Locations(1)

Hong Kong University

Hong Kong, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05336851